Aridis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Aridis Pharmaceuticals

12/08/2021 15:17

* Aridis Pharmaceuticals Inc  ARDS.OQ  reported a quarterly
adjusted loss of 55 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 63 cents per share.
* Revenue fell 96.7% to $33.00 thousand from a year ago; 
analysts expected $300.00 thousand. 
* Aridis Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 49 cents​.
* The mean earnings estimate of analysts had fallen by about 2%
in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate 
* Aridis Pharmaceuticals Inc shares had fallen by 43.2% this
quarter and lost 30.8% so far this year.
* The company reported a quarterly loss of $5.49 million.
* Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $18.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 12 at 02:17 p.m.  ​All
figures in US dollars unless otherwise stated